Grant Award Details

Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)
Grant Type: 
Grant Number: 
CLIN2COVID19-11823
Project Objective: 
  • To evaluate the safety and efficacy of allogeneic bone marrow- derived human mesenchymal stroll cells in COVID-19 positive patients in the conduct a Phase 2 b, randomized , double blind, placebo controlled multi center clinical trial for the treatment of Acute Respiratory Distress Syndrome.
Investigator: 
Disease Focus: 
COVID-19
Infectious Disease
Human Stem Cell Use: 
Adult Stem Cell
Award Value: 
$701,049
Status: 
Active

Grant Application Details

Application Title: 
  • Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)
Public Abstract: 

Therapeutic Candidate or Device

Novel testing of a cell based therapy (Mesenchymal Stromal Cells) for respiratory failure from ARDS.

Indication

COVID-19 positive or negative ARDS patients

Therapeutic Mechanism

It will hopefully improve oxygenation in ARDS patients and potentially decrease mortality.

Unmet Medical Need

There is an unmet need for more effective treatments for ARDS both COVID-19 positive and COVID-19 negative.

Project Objective

Improvement in respiratory function after ARDS

Major Proposed Activities

Assess clinical efficacy of MSC treatment for ARDS in this double-blind, randomized, placebo-controlled trial.

Statement of Benefit to California: 

This new therapy could improve survival from ARDS, a major cause of acute respiratory failure in the citizens of California.

  • Share
PrintPDF version